HomeAI · summaries
Storia in 7 fonti
Abivax ulcerative colitis drug shows strong efficacy, but cases of cancer raise concerns
Abivax said its experimental treatment for ulcerative colitis showed significant efficacy in a closely watched trial, but shares of the company tanked on safety concerns.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
statnews.com
Abivax ulcerative colitis drug shows strong efficacy, but cases of cancer raise concerns
Abivax said its experimental treatment for ulcerative colitis showed significant efficacy in a closely watched trial, but shares of the company tanked on safety concerns.
- ·
biopharmadive.com
AbiVax falls as safety worries cloud ‘landmark’ immune drug results
A handful of cancer cases reported among treatment recipients overshadowed efficacy results analysts described as “best-in-disease” and sent shares down more than 30%.
- ·
cnbc.com
Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update
Shares of French biotech Abivax tumbled 32% after it reported fresh data on its lead asset.
- ·
endpoints.news
Cancer cases weigh down Abivax’s Phase 3 maintenance data in ulcerative colitis
Abivax has proclaimed that its maintenance trial in ulcerative colitis delivered 'landmark' results, and the drug's safety profile has previously been one of its main potential…
- ·
zerohedge.com
Abivax Crashes Most On Record After Cancer Cases In Trial Data Spooks Wall Street
"The cancer signal complicates matters."
- ·
benzinga.com
Why Is Abivax Stock Sinking Tuesday? - Abivax (NASDAQ:ABVX)
Abivax shares plunge more than 35% as cancer cases reported in a Phase 3 trial overshadow strong efficacy results for ulcerative colitis drug.
- ·
qz.com
Abivax stock plunges on cancer signal in ulcerative colitis trial
Jefferies downgraded the French biotech to Hold and cut its price target nearly in half, warning the cancer overhang won't resolve quickly
- ·
Radiopharmaceutical shows promise in post-Pluvicto setting
Abivax's ulcerative colitis data, Fulcrum's scrapped sickle cell drug, and more biotech news from The Readout